Nucleic acid molecule encoding a mismatch endonuclease and methods of use thereof
    2.
    发明授权
    Nucleic acid molecule encoding a mismatch endonuclease and methods of use thereof 有权
    编码错配内切核酸酶的核酸分子及其使用方法

    公开(公告)号:US06699980B1

    公开(公告)日:2004-03-02

    申请号:US09514768

    申请日:2000-02-28

    Inventor: Anthony T. Yeung

    CPC classification number: C12N9/22 C12Q1/683 C12Q2600/156 C12Q2537/113

    Abstract: Nucleic acid molecules encoding a mismatch endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.

    Abstract translation: 提供编码错配核酸内切酶的核酸分子及其用于检测靶向多核苷酸序列突变的方法,其有助于突变,错配和遗传多态性的定位和鉴定。

    Nucleic acid molecule encoding a mismatch endonuclease and methods of use thereof
    3.
    发明授权
    Nucleic acid molecule encoding a mismatch endonuclease and methods of use thereof 有权
    编码错配内切核酸酶的核酸分子及其使用方法

    公开(公告)号:US06391557B1

    公开(公告)日:2002-05-21

    申请号:US09510322

    申请日:2000-02-22

    Inventor: Anthony T. Yeung

    CPC classification number: C12N9/22 C12Q1/683 C12Q2600/156 C12Q2537/113

    Abstract: Nucleic acid molecules encoding a mismatch endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.

    Abstract translation: 提供编码错配核酸内切酶的核酸分子及其用于检测靶向多核苷酸序列突变的方法,其有助于突变,错配和遗传多态性的定位和鉴定。

    Biomarkers for the diagnosis and treatment of pancreatic cancer
    4.
    发明授权
    Biomarkers for the diagnosis and treatment of pancreatic cancer 有权
    用于诊断和治疗胰腺癌的生物标志物

    公开(公告)号:US08609437B2

    公开(公告)日:2013-12-17

    申请号:US12812394

    申请日:2009-01-21

    Abstract: Compositions and methods for use in methods and kits for the detection of an increased risk of pancreatic cancer are provided. Cyst fluid samples isolated from patients that are positive for at least three of the following markers, mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11 indicate that such patients are at greater risk for the development of pancreatic cancer when compared to cyst fluid samples isolated from patients lacking these markers.

    Abstract translation: 提供了用于检测胰腺癌风险增加的方法和试剂盒中的组合物和方法。 对于至少三种以下标记为阳性的患者分离的囊液液样品,粘蛋白1,粘蛋白2,粘蛋白5AC,粘蛋白5B,粘蛋白6,CEA CAM 1,CEACAM 5,CEACAM 6,CEACAM 7,CEACAM 8,S100 -A6,S100-A8,S100-A9和S100-A11表明,与从缺乏这些标记物的患者分离的囊肿液样品相比,这些患者胰腺癌的发展风险更高。

Patent Agency Ranking